# EDGAR Filing Document

**Accession Number:** 0001055951
**File Stem:** 0000947871-23-000250
**Filing Date:** 2023-2
**Character Count:** 58029
**Document Hash:** a7b354b10d4a43660f31a1fd04c1404e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-23-000250.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0000947871-23-000250

**CONFORMED SUBMISSION TYPE**: SC 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**GROUP MEMBERS**: ORBIMED CAPITAL GP VII LLC

**GROUP MEMBERS**: ORBIMED CAPITAL LLC

**GROUP MEMBERS**: ORBIMED GENESIS GP LLC

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enliven Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001672619
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91465
- **FILM NUMBER:** 23684994

**BUSINESS ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** 720-647-8519

**MAIL ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMARA Inc.
- **DATE OF NAME CHANGE:** 20160419
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORBIMED ADVISORS LLC
- **CENTRAL INDEX KEY:** 0001055951
- **IRS NUMBER:** 133976876
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** SC 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 601 LEXINGTON AVENUE
- **STREET 2:** 54TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (212) 739-6400

**MAIL ADDRESS:**
- **STREET 1:** 601 LEXINGTON AVENUE
- **STREET 2:** 54TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

---

| |
|:---|
| **Enliven Therapeutics, Inc.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Name of Issuer)<br>|
| **COMMON STOCK** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Title of Class of Securities)<br>|
| **29337E102** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (CUSIP Number)<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **OrbiMed Advisors LLC**<br> **OrbiMed Capital GP VII LLC**<br> **OrbiMed Genesis GP LLC**<br> **OrbiMed Capital LLC**<br>**601 Lexington Avenue, 54th Floor**<br> **New York, NY 10022**<br> **Telephone: (212) 739-6400**<br>|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Name, Address and Telephone Number of Person Authorized to<br> Receive Notices and Communications)<br>|
| **February 23, 2023** |
| (Date of Event which Requires Filing of this Statement) |

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a Reporting Person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

&nbsp;&nbsp;**CUSIP No. 29337E102**

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons. <br> OrbiMed Advisors LLC | Names of Reporting Persons. <br> OrbiMed Advisors LLC | Names of Reporting Persons. <br> OrbiMed Advisors LLC | Names of Reporting Persons. <br> OrbiMed Advisors LLC |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ |  |
| 3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEC Use Only  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEC Use Only  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEC Use Only  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEC Use Only  |
| 4 | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF |
| 5 | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | □ |
| 6 | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | Sole Voting Power <br> 0 | Sole Voting Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | Shared Voting Power <br> 8,949,339 | Shared Voting Power <br> 8,949,339 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 9 | Sole Dispositive Power <br> 0 | Sole Dispositive Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | Shared Dispositive Power <br> 8,949,339 | Shared Dispositive Power <br> 8,949,339 |
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,949,339 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,949,339 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,949,339 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,949,339 |
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | □ |
| 13 | Percent of Class Represented by Amount in Row (11) <br> 21.8%\* | Percent of Class Represented by Amount in Row (11) <br> 21.8%\* | Percent of Class Represented by Amount in Row (11) <br> 21.8%\* | Percent of Class Represented by Amount in Row (11) <br> 21.8%\* |
| 14 | Type of Reporting Person (See Instructions) <br> IA | Type of Reporting Person (See Instructions) <br> IA | Type of Reporting Person (See Instructions) <br> IA | Type of Reporting Person (See Instructions) <br> IA |

---

\* This percentage is calculated based upon 41,011,501 shares of common stock outstanding of Enliven Therapeutics, Inc. (the "<u>Issuer</u>"), as reported directly by the Issuer.

&nbsp;&nbsp;**CUSIP No. 29337E102**

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons. <br> OrbiMed Capital GP VII LLC | Names of Reporting Persons. <br> OrbiMed Capital GP VII LLC | Names of Reporting Persons. <br> OrbiMed Capital GP VII LLC | Names of Reporting Persons. <br> OrbiMed Capital GP VII LLC |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ |  |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| 4 | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF |
| 5 | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | □ |
| 6 | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | Sole Voting Power <br> 0 | Sole Voting Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | Shared Voting Power <br> 8,661,225 | Shared Voting Power <br> 8,661,225 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 9 | Sole Dispositive Power <br> 0 | Sole Dispositive Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | Shared Dispositive Power <br> 8,661,225 | Shared Dispositive Power <br> 8,661,225 |
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,661,225 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,661,225 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,661,225 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 8,661,225 |
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | □ |
| 13 | Percent of Class Represented by Amount in Row (11) <br> 21.1%\* | Percent of Class Represented by Amount in Row (11) <br> 21.1%\* | Percent of Class Represented by Amount in Row (11) <br> 21.1%\* | Percent of Class Represented by Amount in Row (11) <br> 21.1%\* |
| 14 | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO |

---

\* This percentage is calculated based upon 41,011,501 shares of common stock outstanding of Enliven Therapeutics, Inc. (the "<u>Issuer</u>"), as reported directly by the Issuer.

&nbsp;&nbsp;**CUSIP No. 29337E102**

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons. <br> OrbiMed Genesis GP LLC | Names of Reporting Persons. <br> OrbiMed Genesis GP LLC | Names of Reporting Persons. <br> OrbiMed Genesis GP LLC | Names of Reporting Persons. <br> OrbiMed Genesis GP LLC |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ |  |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| 4 | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF |
| 5 | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | □ |
| 6 | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware | Citizenship or Place of Organization <br> Delaware |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | Sole Voting Power <br> 0 | Sole Voting Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | Shared Voting Power <br> 288,114 | Shared Voting Power <br> 288,114 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 9 | Sole Dispositive Power <br> 0 | Sole Dispositive Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | Shared Dispositive Power <br> 288,114 | Shared Dispositive Power <br> 288,114 |
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 288,114 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 288,114 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 288,114 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 288,114 |
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | □ |
| 13 | Percent of Class Represented by Amount in Row (11) <br> 0.7%\* | Percent of Class Represented by Amount in Row (11) <br> 0.7%\* | Percent of Class Represented by Amount in Row (11) <br> 0.7%\* | Percent of Class Represented by Amount in Row (11) <br> 0.7%\* |
| 14 | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO | Type of Reporting Person (See Instructions) <br> OO |

---

\* This percentage is calculated based upon 41,011,501 shares of common stock outstanding of Enliven Therapeutics, Inc. (the "<u>Issuer</u>"), as reported directly by the Issuer.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**CUSIP No. 29337E102** | &nbsp;&nbsp;**CUSIP No. 29337E102** | &nbsp;&nbsp;**CUSIP No. 29337E102** |  |
| 1 | Names of Reporting Persons. <br> OrbiMed Capital LLC | Names of Reporting Persons. <br> OrbiMed Capital LLC | Names of Reporting Persons. <br> OrbiMed Capital LLC |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ | Check the Appropriate Box if a Member of a Group (See Instructions).<br> (a) □<br> (b) □ |  |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only |
| 4 | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF | Source of Funds (See Instructions) <br> AF |
| 5 | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | □ |
| 6 | Citizenship or Place of Organization <br> Cayman Islands | Citizenship or Place of Organization <br> Cayman Islands | Citizenship or Place of Organization <br> Cayman Islands |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | Sole Voting Power <br> 46,875 | Sole Voting Power <br> 46,875 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | Shared Voting Power <br> 0 | Shared Voting Power <br> 0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 9 | Sole Dispositive Power <br> 46,875 | Sole Dispositive Power <br> 46,875 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | Shared Dispositive Power <br> 0 | Shared Dispositive Power <br> 0 |
| 11 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 46,875 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 46,875 | Aggregate Amount Beneficially Owned by Each Reporting Person <br> 46,875 |
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | □ |
| 13 | Percent of Class Represented by Amount in Row (11) <br> 0.1%\* | Percent of Class Represented by Amount in Row (11) <br> 0.1%\* | Percent of Class Represented by Amount in Row (11) <br> 0.1%\* |
| 14 | Type of Reporting Person (See Instructions) <br> IA | Type of Reporting Person (See Instructions) <br> IA | Type of Reporting Person (See Instructions) <br> IA |

---

\* This percentage is calculated based upon 41,011,501 shares of common stock outstanding of Enliven Therapeutics, Inc. (the "<u>Issuer</u>"), as reported directly by the Issuer.

**Item 1. Security and Issuer**

This Schedule 13D (the "<u>Statement</u>") relates to the common stock, par value $0.001 per share (the "<u>Shares</u>") of Enliven Therapeutics, Inc., a corporation organized under the laws of Delaware (the "<u>Issuer</u>"), with its principal executive offices located at 6200 Lookout Road, Boulder, Colorado 80301. The Shares are listed on the NASDAQ Global Select Market under the ticker symbol "ELVN". Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

The Reporting Persons (as defined below) are filing this Statement as a result of the transactions more particularly described in Item 3 below.

**Item 2. Identity and Background**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Schedule 13D is being filed by OrbiMed Advisors LLC ("<u>OrbiMed Advisors</u>"), OrbiMed Capital GP VII LLC ("<u>OrbiMed GP</u>"), OrbiMed Genesis GP LLC ("<u>OrbiMed Genesis</u>"), and OrbiMed Capital LLC ("<u>OrbiMed Capital</u>") (collectively, the "<u>Reporting Persons</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) — (c), (f) OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member or general partner of certain entities as more particularly described in Item 6 below. OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

OrbiMed GP, a limited liability company organized under the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below. OrbiMed GP has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

OrbiMed Genesis, a limited liability company organized under the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below. OrbiMed Genesis has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

OrbiMed Capital, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment adviser of certain entities as more particularly described in Item 6 below. OrbiMed Capital has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

The directors and executive officers of OrbiMed Advisors, OrbiMed Capital, OrbiMed GP, and OrbiMed Genesis are set forth on Schedules I, II, III, and IV, respectively, attached hereto. Schedules I, II, III, and IV set forth the following information with respect to each such person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) name;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) business address;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) present principal occupation of employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) citizenship.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) — (e) During the last five years, neither the Reporting Persons nor any Person named in Schedules I through IV has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

**Item 3. Source and Amount of Funds or Other Consideration**

Prior to the Merger (as defined below), OrbiMed Private Investments VII, LP ("<u>OPI VII</u>") and OrbiMed Genesis Master Fund, L.P. ("<u>Genesis</u>") were stockholders of Enliven Therapeutics, Inc. ("<u>Old Enliven</u>") and OPI VII and The Biotech Growth Trust PLC ("<u>BIOG</u>") were stockholders of the Issuer. On February 23, 2023, the Issuer, previously named Imara Inc., consummated its merger with Old Enliven in accordance with the terms of an Agreement and Plan of Merger (the "<u>Merger Agreement</u>"), dated as of October 13, 2022, between the Issuer, Old Enliven, and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, Merger Sub was merged with and into Old Enliven (the "<u>Merger</u>"), with Old Enliven continuing as the surviving corporation and a wholly owned subsidiary of the Issuer. Under the terms of the Merger Agreement, each share of Old Enliven common stock was converted into the right to receive 0.2951 Shares. After completion of the Merger, the combined company was renamed "Enliven Therapeutics, Inc."

In addition, prior to the consummation of the merger, the Issuer conducted a 1-to-4 reverse stock split (the "<u>Reverse Stock Split</u>"). References in this Statement to numbers of Shares give effect to the Reverse Stock Split.

The source of funds for such purchases was the working capital of OPI VII and Genesis.

As a result of the transactions described in this Item 3, OrbiMed GP, as the general partner of OPI VII, may be deemed to be the beneficial owners of approximately 21.1% of the outstanding Shares and OrbiMed Genesis, as the general partner of Genesis, may be deemed to be the beneficial owner of 0.7% of the outstanding Shares. OrbiMed Advisors, as the managing member of OrbiMed GP and OrbiMed Genesis, may be deemed to be the beneficial owner of approximately 21.8% of the outstanding Shares. OrbiMed Capital, as the investment advisor to BIOG, may be deemed to be the beneficial owner of 0.1% of the outstanding Shares. None of the Reporting Persons have acquired or disposed of any additional Shares since February 23, 2023.

**Item 4. Purpose of Transaction**

This statement relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients.

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.

Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer's capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer's business or corporate structure, (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) — (b) The following disclosure is based upon 41,011,501 outstanding Shares of the Issuer, as reported directly by the Issuer.

As of the date of this filing, OPI VII, a limited partnership organized under the laws of Delaware, holds 8,661,225 Shares constituting approximately 21.1% of the issued and outstanding Shares. OrbiMed GP is the general partner of OPI VII, pursuant to the terms of the limited partnership agreement of OPI VII, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI VII and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by OPI VII. Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

As of the date of this filing, Genesis, a limited partnership organized under the laws of the Cayman Islands, holds 288,114 Shares constituting approximately 0.7% of the issued and outstanding Shares. OrbiMed Genesis is the general partner of Genesis, pursuant to the terms of the limited partnership agreement of Genesis, and OrbiMed Advisors is the managing member of OrbiMed Genesis, pursuant to the terms of the limited liability company agreement of OrbiMed Genesis. As a result, OrbiMed Advisors and OrbiMed Genesis share power to direct the vote and disposition of the Shares held by Genesis and may be deemed, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by Genesis. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.

As of the date of this filing, BIOG, a publicly-listed investment trust organized under the laws of England, holds 46,875 Shares constituting approximately 0.1% of the issued and outstanding Shares. OrbiMed Capital is the investment advisor of BIOG. As a result, OrbiMed Capital has the power to direct the vote and disposition of the Shares held by BIOG and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner of the Shares held by BIOG. OrbiMed Capital disclaims any beneficial ownership over the shares of the other Reporting Persons. OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by BIOG.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as disclosed in Item 3, the Reporting Persons have not effected any transactions during the past sixty (60) days in any Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Not applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer**

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI VII, pursuant to the terms of the limited partnership agreement of OPI VII. Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI VII. Such authority includes the power to vote and otherwise dispose of securities held by OPI VII. The number of outstanding Shares of the Issuer attributable to OPI VII is 8,661,225. OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI VII, may be considered to hold indirectly 8,661,225 Shares.

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Genesis is the general partner of Genesis, pursuant to the terms of the limited partnership agreement of Genesis. Pursuant to this agreement and relationship, OrbiMed Genesis has discretionary investment management authority with respect to the assets of Genesis. Such authority includes the power to vote and otherwise dispose of securities held by Genesis. The number of outstanding Shares of the Issuer attributable to Genesis is 288,114. OrbiMed Genesis, pursuant to its authority under the limited partnership agreement of Genesis, may be considered to hold indirectly 288,114 Shares.

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Advisors is the managing member of OrbiMed GP and OrbiMed Genesis, pursuant to the terms of the limited liability company agreements of OrbiMed GP and OrbiMed Genesis. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI VII and OrbiMed Advisors and OrbiMed Gensis have discretionary investment management authority with respect to the assets of Genesis. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI VII and OrbiMed Genesis to vote and otherwise dispose of securities held by Genesis. The number of outstanding Shares attributable to OPI VII is 8,661,225 Shares and the number of outstanding Shares attributable to Genesis is 288,114. OrbiMed Advisors, pursuant to its authority under the terms of the limited liability company agreements of OrbiMed GP and OrbiMed Genesis, may also be considered to hold indirectly 8,949,339 Shares.

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Capital is the portfolio manager to BIOG. OrbiMed Capital may be deemed to have voting and investment power over the securities held by BIOG. Such authority includes the power of OrbiMed Capital to vote and otherwise dispose of securities held by BIOG. The number of outstanding Shares attributable to BIOG is 46,875 Shares. OrbiMed Capital, as the portfolio manager to BIOG, may also be considered to hold indirectly 46,875 Shares.

Rishi Gupta ("<u>Gupta</u>"), an employee of OrbiMed Advisors, is a member of the Board of Directors of the Issuer and, accordingly, OrbiMed Advisors and OrbiMed GP may have the ability to affect and influence control of the Issuer. From time to time, Gupta may receive stock options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors. Pursuant to an agreement with OrbiMed Advisors and OrbiMed GP, Gupta is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed GP, which will in turn ensure that such securities or economic benefits are provided to OPI VII.

***Lock-Up Agreement***

In addition, in connection with the Merger, OPI VII and Genesis each entered into a lockup agreement (the "<u>Lock-Up Agreement</u>") with the Issuer pursuant to which, among other things, each of these stockholders agreed not to, except in limited circumstances: (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or any securities convertible, exercisable or exchangeable for Shares; (ii) enter into any hedging, swap, short sale, or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares, whether or not such transaction is to be settled by delivery of Shares, other securities, cash, or other consideration; (iii) make any demand for or exercise any right with respect to the registration of any Shares or other Issuer equity securities; and (iv) publicly disclose the intention to do any of the foregoing, in each case, from the date of the Lock-Up Agreement until 180 days after the closing date of the Merger.

The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lock-Up Agreement, which is filed as Exhibit 2 and incorporated herein by reference.

**Item 7. Material to Be Filed as Exhibits**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;1. | &nbsp;&nbsp;Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC. |
| &nbsp;&nbsp;2. | &nbsp;&nbsp;Form of Lock-Up Agreement. |

---

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Dated: February 28, 2023 | ORBIMED ADVISORS LLC | ORBIMED ADVISORS LLC |
|  | By: | <u>/s/ Carl L. Gordon</u> |
|  |  | Name: Carl L. Gordon |
|  |  | Title: Member |
|  | ORBIMED CAPITAL GP VII LLC | ORBIMED CAPITAL GP VII LLC |
|  | By: | ORBIMED ADVISORS LLC, its managing member |
|  | By: | <u>/s/ Carl L. Gordon</u> |
|  |  | Name: Carl L. Gordon |
|  |  | Title: Member of OrbiMed Advisors LLC<br>|
|  | ORBIMED GENESIS GP LLC | ORBIMED GENESIS GP LLC |
|  | By: | ORBIMED ADVISORS LLC, its managing member |
|  | By: | <u>/s/ Carl L. Gordon</u> |
|  |  | Name: Carl L. Gordon |
|  |  | Title: Member of OrbiMed Advisors LLC<br>|
|  | ORBIMED CAPITAL LLC | ORBIMED CAPITAL LLC |
|  | By: | <u>s/ Carl L. Gordon</u> |
|  |  | Name: Carl L. Gordon |
|  |  | Title: Member |

---

**SCHEDULE I**

The names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022.

---

| | | |
|:---|:---|:---|
| <u>Name</u> | <u>Position with Reporting Person</u> | <u>Principal Occupation</u> |
| Carl L. Gordon | Member | Member<br> OrbiMed Advisors LLC |
| Sven H. Borho<br> German and Swedish Citizen | Member | Member<br> OrbiMed Advisors LLC |
| W. Carter Neild | Member | Member<br> OrbiMed Advisors LLC |
| Geoffrey C. Hsu | Member | Member<br> OrbiMed Advisors LLC |
| C. Scotland Stevens | Member | Member<br> OrbiMed Advisors LLC |
| David P. Bonita | Member | Member<br> OrbiMed Advisors LLC |
| Peter A. Thompson | Member | Member<br> OrbiMed Advisors LLC |
| Matthew S. Rizzo | Member | Member<br> OrbiMed Advisors LLC |
| Trey Block | Chief Financial Officer<br>| Chief Financial Officer<br> OrbiMed Advisors LLC |

---

**SCHEDULE II**

The names and present principal occupations of each of the executive officers and directors of OrbiMed Capital LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022.

---

| | | |
|:---|:---|:---|
| <u>Name</u> | <u>Position with Reporting Person</u> | <u>Principal Occupation</u> |
| Carl L. Gordon | Member | Member<br> OrbiMed Capital LLC |
| Sven H. Borho<br> German and Swedish Citizen | Member | Member<br> OrbiMed Capital LLC |
| W. Carter Neild | Member | Member<br> OrbiMed Capital LLC |
| Geoffrey C. Hsu | Member | Member<br> OrbiMed Capital LLC |
| C. Scotland Stevens | Member | Member<br> OrbiMed Capital LLC |
| David P. Bonita | Member | Member<br> OrbiMed Capital LLC |
| Peter A. Thompson | Member | Member<br> OrbiMed Capital LLC |
| Matthew S. Rizzo | Member | Member<br> OrbiMed Capital LLC |
| Trey Block | Chief Financial Officer<br>| Chief Financial Officer<br> OrbiMed Capital LLC |

---

**SCHEDULE III**

The business and operations of OrbiMed Capital GP VII LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth in Schedule I attached hereto.

**SCHEDULE IV**

The business and operations of OrbiMed Genesis GP LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth in Schedule I attached hereto.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;1. | &nbsp;&nbsp;Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC. |
| &nbsp;&nbsp;2. | &nbsp;&nbsp;Form of Lock-Up Agreement. |

---

## Exhibit 99.1

**<u>Exhibit 1</u>**

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13D, dated February 23, 2023, with respect to the common stock of Enliven Therapeutics, Inc.. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 28<sup>th</sup> day of February 2023.

---

| | |
|:---|:---|
| ORBIMED ADVISORS LLC | ORBIMED ADVISORS LLC |
| By: | <u>/s/ Carl L. Gordon</u> |
|  | Name: Carl L. Gordon |
|  | Title: Member |
| ORBIMED CAPITAL GP VII LLC | ORBIMED CAPITAL GP VII LLC |
| By: | ORBIMED ADVISORS LLC, its managing member |
| By: | <u>/s/ Carl L. Gordon</u> |
|  | Name: Carl L. Gordon |
|  | Title: Member of OrbiMed Advisors LLC<br>|
| ORBIMED GENESIS GP LLC | ORBIMED GENESIS GP LLC |
| By: | ORBIMED ADVISORS LLC, its managing member |
| By: | <u>/s/ Carl L. Gordon</u> |
|  | Name: Carl L. Gordon |
|  | Title: Member of OrbiMed Advisors LLC<br>|
| ORBIMED CAPITAL LLC | ORBIMED CAPITAL LLC |
| By: | <u>s/ Carl L. Gordon</u> |
|  | Name: Carl L. Gordon |
|  | Title: Member |

---

## Exhibit 99.2

**LOCK-UP AGREEMENT**

October 13, 2022

Enliven Therapeutics, Inc.

Ladies and Gentlemen:

The undersigned signatory of this lock-up agreement (this "<u>Lock-Up Agreement</u>") understands that Imara Inc., a Delaware corporation ("<u>Public Company</u>"), has entered into an Agreement and Plan of Merger, dated as of October 13, 2022 (as the same may be amended from time to time, the "<u>Merger Agreement</u>") with Iguana Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Public Company, and Enliven Therapeutics, Inc., a Delaware corporation ("<u>Merger Partner</u>"). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.

As a condition and inducement to Public Company to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Public Company, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the "<u>Restricted Period</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Public Company Common Stock or any securities convertible into or exercisable or exchangeable for Public Company Common Stock (including without limitation, Public Company Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Public Company which may be issued upon exercise or vesting, as applicable, of an option, warrant, restricted stock award or restricted stock unit, in each case to purchase, receive in the future or otherwise acquire Public Company Common Stock (collectively, "<u>Public Company Equity Rights</u>")) that are currently or hereafter owned by the undersigned (collectively, the "<u>Undersigned's Shares</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned's Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of Public Company Common Stock or other securities, in cash or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) make any demand for, or exercise any right with respect to, the registration of any shares of Public Company Common Stock or Public Company Equity Rights (other than (i) such rights set forth in the Merger Agreement and (ii) the exercise of piggyback registration rights in connection with any secondary underwritten public offering of the Public Company Common Stock); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) publicly disclose the intention to do any of the foregoing.

The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) transfers of the Undersigned's Shares:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) if the undersigned is a <u>natural person</u>, (A) to any person related to the undersigned by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a "<u>Family Member</u>"), or to a trust formed for the benefit of the undersigned or any of the undersigned's Family Members, (B) to the undersigned's estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) if the undersigned is a <u>corporation, partnership or other entity</u>, (A) to another corporation, partnership, or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that control or manage, are under common control or management with, or are controlled or managed by the undersigned (including, for the avoidance of doubt, a fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by or under common control with such manager or managing member or general partner or management company as the undersigned), (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned's equity holders), (C) as a bona fide gift or a charitable contribution or (D) transfers or dispositions not involving a change in beneficial ownership; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) if the undersigned is a <u>trust</u>, to any grantors or beneficiaries of the trust;

<u>provided</u> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Public Company a lock-up agreement in the form of this Lock-Up Agreement with respect to the shares of Public Company Common Stock or Public Company Equity Rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the exercise or settlement of any Public Company Equity Rights (including a net or cashless exercise), and any related transfer of shares of Public Company Common Stock to Public Company for the purpose of paying the exercise price of such Public Company Equity Rights or for paying taxes (including estimated taxes or tax withholding obligations) due as a result of such exercise; <u>provided</u> that, for the avoidance of doubt, the underlying shares of Public Company Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Public Company Common Stock; <u>provided</u> that such plan does not provide for any transfers of Public Company Common Stock during the Restricted Period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) transfers by the undersigned of shares of Public Company Common Stock purchased by the undersigned on the open market or in a public offering by Public Company, in each case following the date of the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Public Company's capital stock involving a change of control of Public Company, <u>provided</u> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned's Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) pursuant to an order of a court or regulatory agency;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any shares of Public Company Common Stock issued pursuant to the Merger Agreement in respect of shares of Merger Partner, if any, purchased from the Merger Partner in the Financing; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) consented to by the Merger Partner.

and <u>provided</u>, further, that, with respect to each of (a), (b), and (c), above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than (x) any exit filings or public announcements that may be required under applicable federal and state securities Laws or (y) in respect of a required filing under the Exchange Act in connection with the exercise or the net settlement of any Public Company Equity Right, settled in Public Company Common Stock, that would otherwise expire during the Restricted Period, provided that reasonable notice shall be provided to Public Company prior to any such filing).

Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Public Company. In furtherance of the foregoing, the undersigned agrees that Public Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Public Company may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned's ownership of Public Company Common Stock:

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY

OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.

The undersigned understands that if the Merger Agreement is terminated for any reason, this Lock-Up Agreement will automatically terminate, and the undersigned shall be released from all of his, her or its obligations under this Lock-Up Agreement. The undersigned understands that Public Company is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement. This Lock-Up Agreement will automatically terminate, and the undersigned will be released from all of his, her or its obligations hereunder, upon the date that is six (6) months after the date of the Merger Agreement in the event that transactions contemplated by the Merger Agreement have not been consummated by such date.

Any and all remedies herein expressly conferred upon Public Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Public Company of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable damage would occur to Public Company in the event that any provision of this Lock-Up Agreement was not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that Public Company shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Public Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Public Company with respect thereto.

In the event that any holder of Public Company's securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Public Company to sell or otherwise transfer or dispose of shares of Public Company Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder, the same percentage of shares of Public Company Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Public Company Common Stock held by such holder on the date of such release or waiver that are subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the "<u>Pro-Rata Release</u>"); <u>provided</u>, <u>however</u>, that such Pro-Rata Release shall not be applied unless and until permission has been granted by Public Company to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Public Company Common Stock in an aggregate amount in excess of 1% of the number of shares of Public Company Common Stock originally subject to a substantially similar agreement. The Public Company shall notify the undersigned within two (2) business days prior to the effective date of

a release of any holder of Public Company Common Stock of such holder's obligations under a lock-up or substantially similar agreement that gives rise to a Pro-Rata Release.

Upon the release of any of the Undersigned's Shares from this Lock-Up Agreement, Public Company will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.

This Lock-Up Agreement and any claim, controversy or dispute arising under or related to this Lock-Up Agreement shall be governed by and construed in accordance with the Laws of the state of Delaware, without regard to the conflict of Laws principles thereof.

This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by Public Company and the undersigned by facsimile or electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this Lock-Up Agreement.

*[SIGNATURE PAGE FOLLOWS]*

---

| |
|:---|
| &nbsp;&nbsp;Very truly yours, |
| &nbsp;&nbsp;**ORBIMED PRIVATE<br> INVESTMENTS VII, L.P.** |
| &nbsp;&nbsp;By: OrbiMed Capital GP VII LLC,<br> its General Partner |
| &nbsp;&nbsp;By: OrbiMed Advisors LLC,<br> its Managing Member |
| &nbsp;&nbsp;By: ______________________________<br> Name:<br> Title: |
| &nbsp;&nbsp;**ORBIMED GENESIS MASTER<br> FUND, L.P.** |
| &nbsp;&nbsp;By: OrbiMed Genesis GP LLC,<br> its General Partner |
| &nbsp;&nbsp;By: OrbiMed Advisors LLC,<br> its Managing Member |
| &nbsp;&nbsp;By: ______________________________<br> Name:<br> Title: |

---

*[Signature Page to Lock-Up Agreement]*

Accepted and Agreed<br> by Imara Inc.: <br> <u>________________________________</u><br> Name:<br> Title: <br>

*[Signature Page to Lock-Up Agreement]*